×
Home Companies Industry Politics Money Opinion LoungeMultimedia Science Education Sports TechnologyConsumerSpecialsMint on Sunday
×

USFDA allows Sun Pharma subsidiary to market antidepressant drug

USFDA allows Sun Pharma subsidiary to market antidepressant drug
PTI
Comment E-mail Print Share
First Published: Thu, Apr 08 2010. 11 58 AM IST
Updated: Thu, Apr 08 2010. 11 58 AM IST
Mumbai: Sun Pharmaceutical on Thursday said its subsidiary has received approval from the US health regulator to market Bupropion Hydrochloride antidepressants tablets.
The US-based subsidiary of the company has received Food and Drug Administration approval to market its drug Bupropion Hydrochloride Bupropion Hydrochloride Extended-Release, Sun Pharmaceutical said in a filing to the Bombay Stock Exchange.
These tablets are available in strengths of 100 mg, 150 mg and 200 mg, the filing added.
Bupropion Hydrochloride Extended-Release tablets are used for the treatment of major depressive disorder.
These tablets are generic equivalent of GlaxoSmithKline’s Wellbutrin SR tablets.
Comment E-mail Print Share
First Published: Thu, Apr 08 2010. 11 58 AM IST